Prelude Therapeutics Incorporated (PRLD) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-2.4%

$3.75

vs $3.84 price

Levered DCF

$1.02

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

-3.06

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-2.25×	-0.76×	-2.11×	-2.66×	-5.34×	-55.04×	-30.82×	-2.81×
P/B	3.25×	0.73×	1.09×	1.46×	2.07×	14.74×	-17.18×	-1.82×
P/S	18.38×	13.75×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-1.48×	-0.6×	-1.48×	-1.57×	-3.61×	-35.21×	-21.53×	-0.97×
Gross margin	85.9%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-861.3%	-1995.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-819.6%	-1816.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	1.99×	5.3×	10.79×	9.42×	15.37×	19.41×	4.18×	6.37×
Debt / equity	0.26×	0.14×	0.07×	0.01×	0.01×	0×	-0.01×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-145.0%	-96.7%	-51.4%	-59.1%	-39.1%	-26.8%	55.8%	64.7%
Return on invested capital	-114.8%	-91.6%	-51.4%	-61.6%	-39.5%	-27.7%	-162.5%	-107.3%
Return on assets	-70.4%	-72.5%	-43.9%	-52.4%	-36.6%	-25.5%	-126.1%	-89.5%
Free cash flow yield	-25.3%	-107.7%	-42.9%	-30.3%	-14.5%	-1.5%	-3.1%	-32.7%
Earnings yield	-44.6%	-132.1%	-47.3%	-40.3%	-18.8%	-1.8%	-3.2%	-35.6%
Enterprise value	$144.4M	$75.4M	$178.5M	$178.7M	$399.7M	$2B	$597.1M	$14.4M
Net debt / EBITDA	0.18×	-0.04×	0.07×	0.25×	0.27×	3.75×	0.67×	1.05×
Cash conversion cycle (days)	-850	0	0	0	0	0	0	-3,336